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Introduction {#sec001}
============

Ocular blood flow has been known as a major risk factor for glaucoma development and progression \[[@pone.0194533.ref001]\]. Although this association is difficult to study because different techniques are used for measuring different aspects of ocular circulation \[[@pone.0194533.ref002]\], reduced ocular blood flow has been known to occur in both early and late stages of glaucoma \[[@pone.0194533.ref003], [@pone.0194533.ref004]\]. This phenomenon can be observed within the optic nerve head \[[@pone.0194533.ref005]\], retinal circulation, choroid \[[@pone.0194533.ref006]\], retrobulbar \[[@pone.0194533.ref007]\], and even peripheral blood flow \[[@pone.0194533.ref008]\]. Reduced ocular blood flow seems to be more frequently found and more severe in normal-tension glaucoma than in high-tension glaucoma \[[@pone.0194533.ref009]\]. Furthermore, differences in blood flow reduction were more pronounced under provocation in glaucoma \[[@pone.0194533.ref010]\] and were also more pronounced in progressive than in nonprogressive eyes \[[@pone.0194533.ref011], [@pone.0194533.ref012]\]. Many studies have shown that the reduction of ocular blood flow definitely plays an important role in glaucoma development or progression \[[@pone.0194533.ref001], [@pone.0194533.ref013]--[@pone.0194533.ref022]\].

Reduced ocular blood flow has been known to be related to systemic hemodynamic changes. For example, the 9-year follow-up Barbados Eye Studies revealed that patients with lower systolic, diastolic, and mean ocular perfusion pressure levels had a significantly increased risk of developing open-angle glaucoma (OAG) (relative risk, 2.6 for low mean perfusion pressure \[\< 40 mmHg\]). This longitudinal result supports the notion of reduced ocular perfusion pressure as a risk factor for OAG development \[[@pone.0194533.ref023]\]. In the Los Angeles Latino Eye Study, the authors found that lower diastolic (odds ratio \[OR\] = 1.9), systolic (OR = 2.5), and mean (OR = 3.6) ocular perfusion pressure levels were associated with a higher prevalence of OAG \[[@pone.0194533.ref024]\].

Patients with severe carotid artery diseases (CAS) may show retrobulbar hemodynamic changes and a greater risk of developing ocular ischemic syndrome \[[@pone.0194533.ref025]\]. Recently, Hayreh and Zimmerman enrolled 614 patients (728 eyes) with an ocular arterial occlusive disorder such as nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, branch retinal artery occlusion, ocular ischemic syndrome, and amaurosis fugax \[[@pone.0194533.ref026]\]. They revealed that all patients had carotid artery diseases, and concluded that the ophthalmic artery originating from an atherosclerotic internal carotid artery has a markedly stenosed lumen at its origin. Under such conditions, ophthalmic artery stenosis is the primary cause of the reduction of ocular blood perfusion \[[@pone.0194533.ref026], [@pone.0194533.ref027]\]. However, they did not include patients with glaucoma in their cohort \[[@pone.0194533.ref026]\].

The role of carotid artery diseases in the pathogenesis of OAG has remained debatable in recent decades \[[@pone.0194533.ref001], [@pone.0194533.ref009], [@pone.0194533.ref028], [@pone.0194533.ref029]\]. In 1966, Moskovchenko et al analyzed 123 patients with OAG and concluded that the progression of the glaucomatous process was connected to sclerotic changes in the internal carotid and ophthalmic arteries in a number of patients \[[@pone.0194533.ref030]\]. However, Jampol et al followed 5 patients with severe bilateral CAS with increasing intraocular pressure for 3 to 12 years without developing glaucomatous disc or field changes \[[@pone.0194533.ref031]\]. Moreover, Bunin et al did not reveal any primary OAG in patients with CAS \[[@pone.0194533.ref032]\]. Greenfield and his colleagues also showed that the prevalence of hemodynamically significant CAS was not correlated with glaucoma severity \[[@pone.0194533.ref033]\].

Although most previous studies have suggested a correlation between reduced blood flow in various ocular tissues and OAG, whether CAS is a risk factor for OAG remains unclear. We hypothesized that the reduction of ocular perfusion caused by CAS would increase the risk of OAG. The objective of the current study was to investigate the association between CAS and the development of OAG in the Taiwanese population.

Methods {#sec002}
=======

Study design and dataset {#sec003}
------------------------

This was a population-based retrospective cohort study utilizing the Longitudinal Health Insurance Database (LHID2000), which is managed the Taiwan National Health Research Institute (NHRI). The Taiwan NHI program was introduced in 1995 and is mandatory for all citizens in Taiwan to join, except for people who are not regular residents of Taiwan. The coverage rate of this program is approximately 99% \[[@pone.0194533.ref034]\]. The LHID includes the claims data of 1 million randomly sampled individuals from the total 23 million NHI beneficiaries. The NHRI report revealed no statistically significant differences in age, sex, or area distribution between the cohorts in the LHID and in the Taiwan NHI \[[@pone.0194533.ref034]\]. This study was approved by the Ethics Review Board of Taichung Veterans General Hospital (CE13152B-3).

Case definition {#sec004}
---------------

We enrolled patients with CAS aged ≥18 years as the study cohort. These patients had claims with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 433.10 and 433.11 from 1999 to 2010 from 1 inpatient or 3 outpatient visits. The index date was the date of an initial diagnosis of CAS. For the comparison group, we randomly selected patients from the LHID who did not receive a diagnosis of CAS and matched them to the patients by age and sex in a 4:1 ratio. The index date for patients in the comparison group was matched to the same date of the diagnosis of CAS in the case group. Patients with glaucoma (ICD-9-CM 365) before the index date in CAS patients and comparison subjects were excluded from the study. [Fig 1](#pone.0194533.g001){ref-type="fig"} shows the flowchart for study population selection.

![Flowchart of study population selection.](pone.0194533.g001){#pone.0194533.g001}

Study outcomes {#sec005}
--------------

The primary outcome was diagnosis of incident open-angle glaucoma. For this study, the definition of open-angle glaucoma required the diagnosis of glaucoma or ocular hypertension (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9: 365.X or 364.22). We excluded glaucoma patients with ICD-9: 365.2X, 364.22, 365.3X, 365.4X, 365.5X, and 365.6X or a history of glaucoma laser iridotomy or peripheral iridectomy for more strict definition for other ill-defined glaucoma in Taiwanese patients \[[@pone.0194533.ref035]\]. All of the patients had the same diagnosis at least 3 consequent visits and received the visual field examination during the visits. The censor of the study was defined as the subjects withdrawing the health insurance, glaucoma with laser iridotomy procedure or until December 31, 2013. Because several underlying diseases may affect open-angle glaucoma, we considered age, sex, hypertension (ICD-9-CM 401--405), hyperlipidemia (ICD-9-CM 272), diabetes (ICD-9-CM 250), migraine (ICD-9-CM 346), thyroid disease (ICD-9-CM 240--246), and heart failure (ICD-9-CM 428) as potential comorbidities in our study.\[[@pone.0194533.ref036]\] Carotid endarterectomy and carotid artery stenting are the surgical treatment options for CAS \[[@pone.0194533.ref037]\]. The number of topical antiglaucoma medications each patient was given was also analyzed. Combined antiglaucoma medications were considered to be 2 different antiglaucoma medications in our analysis.

Statistical analysis {#sec006}
--------------------

To examine the differences between the case cohort and the comparison cohort, a chi-squared test was used for categorical variables such as sex and comorbidities and the *t* test was applied for continuous variables. The hazard ratios (HRs) with 95% CIs of incident OAG were determined by the Cox proportional hazard model. The model was adjusted for age, sex, hypertension, hyperlipidemia, diabetes, migraine, TD and heart failure. The curve of cumulative incidence of OAG was assessed by the Kaplan-Meier method, with statistical significance examined by the log-rank test.

All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA), and the incidence curve was plotted by R software (R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were 2 sided, conducted at a significance level of 0.05, and reported using *P* values and 95% CIs.

Results {#sec007}
=======

[Table 1](#pone.0194533.t001){ref-type="table"} shows the demographic characteristics of the 2093 patients in the CAS cohort and the 8372 patients in the comparison cohort. Both cohorts exhibited similar distributions regarding sex and age. Both cohorts were predominantly composed of men (64.5%) and had an average age of 69 years. Compared with the comparison cohort, the CAS cohort had a significantly higher proportion of several comorbidities including hypertension (82.4% vs 57.6%), hyperlipidemia (47.1% vs 30.6%), diabetes (37.9% vs 24.5%), migraine (4.30% vs 2.44%), and heart failure (13.6% vs 8.09%).

10.1371/journal.pone.0194533.t001

###### Demographic characteristics of patients with CAS (CAS cohort) and patients without CAS (comparison cohort).

![](pone.0194533.t001){#pone.0194533.t001g}

  ----------------------------------------------------------------
  Variable          Comparison cohort\   CAS cohort\   *P* value
                    N = 8372             N = 2093      
  ----------------- -------------------- ------------- -----------
  Age, years (SD)   69.1 (11.8)          69.2 (11.7)   0.61

  Sex                                                  \>0.99

   Female           2972 (35.5)          743 (35.5)    

   Male             5400 (64.5)          1350 (64.5)   

  Comorbidity                                          

   Hypertension     4821 (57.6)          1725 (82.4)   \<0.0001

   Hyperlipidemia   2558 (30.6)          986 (47.1)    \<0.0001

   Diabetes         2047 (24.5)          793 (37.9)    \<0.0001

   Migraine         204 (2.44)           90 (4.30)     \<0.0001

   TD               268 (3.20)           84 (4.01)     0.07

   Heart failure    677 (8.09)           285 (13.6)    \<0.0001
  ----------------------------------------------------------------

CAS, carotid artery stenosis; TD, thyroid disease.

After adjustment for age, sex, hypertension, hyperlipidemia, diabetes, migraine, thyroid disease, and heart failure, patients with CAS still had a 1.50-fold higher risk of OAG than did the patients in the comparison group in our Cox model ([Table 2](#pone.0194533.t002){ref-type="table"}; adjusted HR = 1.50, 95% CI, 1.11--2.02, *P* = .008). As illustrated in [Fig 2](#pone.0194533.g002){ref-type="fig"}, Kaplan-Meier analysis revealed that patients with CAS had a higher cumulative incidence of OAG than did the comparison cohort during the follow-up period (log-rank test, *P* = .0008). The median follow-up time and interquartile range for the CAS and comparison cohorts were 5.80 (5.03) and 5.12 (4.66) years, respectively.

![Cumulative incidence of open-angle glaucoma in patients with and without carotid artery stenosis.\
The carotid artery stenosis cohort had a higher cumulative incidence of open-angle glaucoma than did the matched cohort (*P \<* .001 by log-rank test).](pone.0194533.g002){#pone.0194533.g002}

10.1371/journal.pone.0194533.t002

###### Incidence rate and HR of open-angle glaucoma in patients with carotid artery stenosis and the comparison cohort.

![](pone.0194533.t002){#pone.0194533.t002g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes         Event   Person-years   Incidence[\*](#t002fn001){ref-type="table-fn"}   Crude HR\          Adjusted HR[\*\*](#t002fn002){ref-type="table-fn"}\   p value
                                                                                           (95% CI)           (95% CI)                                              
  ---------------- ------- -------------- ------------------------------------------------ ------------------ ----------------------------------------------------- ---------
  CAS                                                                                                                                                               

   No              174     54545          31.9                                             ref                ref                                                   \-

   Yes             63      12079          52.2                                             1.63(1.22--2.17)   1.50(1.11--2.02)                                      0.008

  Age                                                                                                                                                               

   \<65            77      23019          33.5                                             ref                ref                                                   \-

   65--75          109     25583          42.6                                             1.27(0.95--1.70)   1.19(0.88--1.61)                                      0.25

   \>75            51      18022          28.3                                             0.83(0.58--1.18)   0.76(0.53--1.10)                                      0.15

  Sex                                                                                                                                                               

   Female          86      24527          35.1                                             ref                ref                                                   \-

   Male            151     42096          35.9                                             1.02(0.78--1.33)   1.02(0.78--1.33)                                      0.91

  Hypertension                                                                                                                                                      

   No              80      26834          29.8                                             ref                ref                                                   \-

   Yes             157     39789          39.5                                             1.32(1.00--1.72)   1.14(0.84--1.55)                                      0.39

  Hyperlipidemia                                                                                                                                                    

   No              149     45427          32.8                                             ref                ref                                                   \-

   Yes             88      21196          41.5                                             1.26(0.96--1.63)   1.04(0.78--1.39)                                      0.78

  Diabetes                                                                                                                                                          

   No              164     50357          32.6                                             ref                ref                                                   \-

   Yes             73      16267          44.9                                             1.37(1.04--1.80)   1.22(0.90--1.64)                                      0.20

  Migraine                                                                                                                                                          

   No              228     64995          35.1                                             ref                ref                                                   \-

   Yes             9       1628           55.3                                             1.56(0.80--3.03)   1.48(0.76--2.89)                                      0.25

  TD                                                                                                                                                                

   No              234     64534          36.3                                             ref                ref                                                   \-

   Yes             3       2089           14.4                                             0.39(0.13--1.23)   0.36(0.11--1.13)                                      0.08

  Heart failure                                                                                                                                                     

   No              216     62139          34.8                                             ref                ref                                                   \-

   Yes             21      4485           46.8                                             1.33(0.85--2.08)   1.25(0.79--1.99)                                      0.34
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Incidence rate: per 10 000 person-years.

\*\*Adjusted for age, sex, hypertension, hyperlipidemia, diabetes, migraine, TD and heart failure.

CAS, carotid artery stenosis; TD, thyroid disease; HR, hazard ratio.

After stratification by age and sex, comparing the risk of OAG in the CAS cohort with that in the comparison cohort showed that in the \<65-year age group, patients with CAS were significantly associated with a 2.47-fold higher risk of developing OAG ([Table 3](#pone.0194533.t003){ref-type="table"}; HR = 2.47, 95% CI, 1.49--4.09). Moreover, male patients with CAS had a 1.59-fold higher risk of OAG did those in the comparison group ([Table 3](#pone.0194533.t003){ref-type="table"}; HR = 1.59, 95% CI, 1.09--2.31).

10.1371/journal.pone.0194533.t003

###### Subgroup analysis stratified by age and sex.

![](pone.0194533.t003){#pone.0194533.t003g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                           Comparison cohort   CAS cohort   Adjusted HR\   P value                                    
                                                                                       (95% CI)                                                  
  --------------------------------------------------- ------------------- ------------ -------------- --------- ------ ------ ------------------ --------
  Age groups[\*\*](#t003fn002){ref-type="table-fn"}                                                                                              

   \<65                                               48                  18851        25.5           29        4168   69.6   2.47(1.49--4.09)   0.0005

   65--75                                             86                  20928        41.1           23        4655   49.4   1.13(0.71--1.82)   0.60

   \>75                                               40                  14766        27.1           11        3256   33.8   1.12(0.57--2.21)   0.74

  Sex[\*\*\*](#t003fn003){ref-type="table-fn"}                                                                                                   

   Female                                             63                  20067        31.4           23        4460   51.6   1.36(0.83--2.23)   0.22

   Male                                               111                 34478        32.2           40        7618   52.5   1.59(1.09--2.31)   0.02
  -------------------------------------------------------------------------------------------------------------------------------------------------------

\*Incidence rate: per 10,000 person-years.

\*\*adjusted for sex, hypertension, hyperlipidemia, diabetes, migraine, TD and heart failure.

\*\*\*adjusted for age, hypertension, hyperlipidemia, diabetes, migraine, TD and heart failure.

PYs, patient-years; CAS, carotid artery stenosis; TD, thyroid disease.

The risk of developing OAG in the subgroup of CAS without surgical treatment was significantly higher than that in the comparison group ([Table 4](#pone.0194533.t004){ref-type="table"}; HR = 1.57, 95% CI, 1.16--2.13). However, the risk of developing OAG in the subgroup of CAS with surgical treatment was not significantly different from that in the comparison group (HR = 0.79, 95% CI, 0.25--2.49).

10.1371/journal.pone.0194533.t004

###### Risk of developing open-angle glaucoma in the comparison cohort, CAS without treatment subgroup, and CAS with treatment subgroup.

![](pone.0194533.t004){#pone.0194533.t004g}

  ---------------------------------------------------------------------------------------
  Variables               N      Event   PYs     Incidence   Adjusted HR\       P value
                                                             (95% CI)           
  ----------------------- ------ ------- ------- ----------- ------------------ ---------
  Comparison cohort       8372   174     54545   31.9        ref                

  CAS without treatment   1918   60      11043   54.3        1.57(1.16--2.13)   0.004

  CAS with treatment      175    3       1036    29.0        0.79(0.25--2.49)   0.69
  ---------------------------------------------------------------------------------------

Incidence rate: per 10 000 person-years.

Treatment: surgical treatment including carotid endarterectomy and carotid artery stenting.

Adjusted for age, sex, hypertension, hyperlipidemia, diabetes, migraine, TD and heart failure.

PYs, patient-years; CAS, carotid artery stenosis; TD, thyroid disease.

In the comparison cohort, 39.1%, 48.3%, and 12.6% of patients with OAG received 0, 1, and 2 or more antiglaucoma medications prescribed at diagnosis, respectively. In the CAS cohort, 47.6%, 46.0%, and 6.35% of patients with OAG received 0, 1, and 2 or more antiglaucoma medications prescribed at diagnosis, respectively. Furthermore, in the comparison cohort, 27.4%, 38.2%, and 34.4% of patients with OAG received 0, 1, and 2 or more antiglaucoma medications prescribed 1 year after the diagnosis of OAG, respectively. In the CAS cohort, 34.5%, 37.9%, and 27.6% of patients with OAG received 0, 1, and 2 or more antiglaucoma medications prescribed 1 year after the diagnosis of OAG, respectively. However, there was no statistical difference in the number of antiglaucoma medications between both cohorts ([Table 5](#pone.0194533.t005){ref-type="table"}).

10.1371/journal.pone.0194533.t005

###### Number of antiglaucoma medications prescribed in patients with CAS and the comparison cohort.

![](pone.0194533.t005){#pone.0194533.t005g}

  Number of Antiglaucoma medications   At glaucoma diagnosis   1 year after the diagnosis of OAG                                  
  ------------------------------------ ----------------------- ----------------------------------- ------ ----------- ----------- ------
  0                                    68 (39.1)               30 (47.6)                           0.28   43 (27.4)   20 (34.5)   0.51
  1                                    84 (48.3)               29 (46.0)                                  60 (38.2)   22 (37.9)   
  2+                                   22 (12.6)               4 (6.35)                                   54 (34.4)   16 (27.6)   

CAS, carotid artery stenosis; OAG, open-angle glaucoma.

Discussion {#sec008}
==========

According to our results, Kaplan-Meier analysis revealed that patients with CAS had a higher cumulative incidence of OAG than did the comparison cohort during the follow-up period (log-rank test, *P* = .0008). Age, sex, hypertension, hyperlipidemia, diabetes mellitus, migraine, thyroid disease, and heart failure are known to be the risk factors for OAG \[[@pone.0194533.ref038]\]. After adjustment for these risk factors in our analysis, patients with CAS had a higher risk of OAG (adjusted HR = 1.50, 95% CI, 1.11--2.02). These results support our hypothesis that CAS is an independent risk factor for OAG. Our results are consistent with those of a previous study that showed a markedly higher rate of CAS in patients with OAG \[[@pone.0194533.ref039]\].

CAS results in reduced blood pressure in the ocular vascular bed, consequently engendering reduced ocular blood flow \[[@pone.0194533.ref026]\]. The results of the Los Angeles Latino Eye Study, Barbados Studies, Rotterdam Study, and studies in Hispanic adults support the notion of low ocular perfusion pressure as a risk factor for OAG development \[[@pone.0194533.ref023], [@pone.0194533.ref024], [@pone.0194533.ref040], [@pone.0194533.ref041]\]. Previous studies have also suggested reduced blood flow in various ocular tissues in patients with OAG \[[@pone.0194533.ref001], [@pone.0194533.ref042]\]. Cherecheanu et al proposed a model including primary and secondary insults in glaucoma. In this model, ischemia at the optic nerve head causes primary insult to retinal ganglion cell axons, whereas the ocular perfusion pressure falling below the limit of autoregulation will result in the secondary insults \[[@pone.0194533.ref043]\]. This proposed model can explain the results in our study.

Our results also demonstrate that patients with CAS aged \<65 years were significantly associated with a 2.47-fold higher risk of OAG compared with the comparison cohort (HR = 2.47, 95% CI, 1.49--4.09). Male patients had a 1.59-fold higher risk of OAG than did those in the comparison cohort (HR = 1.59, 95% CI, 1.09--2.31). These results indicate that CAS is an important risk factor for OAG, particularly in male patients aged younger than 65 years. This is a novel finding that should be recognized as an independent risk factor in patients with OAG who are aged younger than 65 years.

Carotid endarterectomy and carotid artery stenting are the surgical treatment options for CAS \[[@pone.0194533.ref037]\]. The results of the Asymptomatic Carotid Surgery Trial \[[@pone.0194533.ref044]\] and the Asymptomatic Carotid Atherosclerosis Study have shown decreased risks of ipsilateral strokes at 5 years after carotid endarterectomy compared with medical therapy \[[@pone.0194533.ref045]\]. The North American Symptomatic Carotid Endarterectomy Trial also revealed that carotid endarterectomy could significantly reduce the incidence of ipsilateral cerebral events in patients with internal carotid artery greater than 70% stenosis \[[@pone.0194533.ref046]\]. Carotid artery stenting is a proposed alternative to carotid endarterectomy for both symptomatic and asymptomatic high-risk surgical candidates \[[@pone.0194533.ref047]\]. The current study also revealed a reduced HR of OAG with carotid endarterectomy or carotid artery stenting versus medical therapy. Our results imply that carotid endarterectomy or carotid artery stenting might improve ocular hemodynamics in patients with CAS and further reduce the risk of OAG. Our results are compatible with the findings of Kozobolis et al, which revealed that carotid endarterectomy could improve retrobulbar blood flow and perimetric parameters in patients with glaucoma,\[[@pone.0194533.ref048]\] and of other studies that have shown that carotid artery stenting could also improve chronic ocular ischemic syndrome and increase ocular circulation caused by severe CAS \[[@pone.0194533.ref049]--[@pone.0194533.ref051]\].

This study has the following limitations. First, clinical data such as intraocular pressure, central corneal thickness, visual field, optical coherence tomography, and optic nerve images are unavailable in the claims database. Second, CAS may have been underdiagnosed in this population because many patients with CAS are asymptomatic. Third, abnormal structure of the anterior chamber angle, genetic background, and CAS severity were also unavailable in our database. Fourth, OAG may have been underdiagnosed in this population because early-stage glaucoma has few warning signs or symptoms. Additional studies are required to confirm our epidemiological survey in order to clarify the underlying pathophysiological mechanisms responsible for the association between CAS and OAG.

Conclusion {#sec009}
==========

This is the first nationwide population-based study assessing the association between CAS and OAG. We found that patients with CAS had a significantly higher risk of OAG after adjustment for age, sex, and other confounders. This result indicates that CAS is an independent risk factor for OAG. Our finding is clinically important due to the increasing prevalence of CAS in the aging population. To facilitate early diagnosis and treatment, we suggest early referral of patients with CAS to ophthalmologists.
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